Effectiveness of Isoniazid Treatment for Latent Tuberculosis Infection among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Injection Drug Users in Methadone Programs

Clinical Infectious Diseases

Volumn 37, Issue 12, 2003, Pages 1686-1692

  Scholten, Jerod N ^a   Driver, Cynthia R ^a,f   Munsiff, Sonal S ^a   Kaye, Katherine ^a   Rubino, Mary Ann ^a   Gourevitch, Marc N ^d   Trim, Caroline ^b   Amofa, James ^d   Seewald, Randy ^b   Highley, Esther ^c   Fujiwara, Paula I ^a,e  

^a NY City Dept of Hlth/Mental Hyg   (United States)

^b Greenwich House   (United States)

^c Lower Eastside Service Center Inc   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Bureau of STD Control   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULIN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; FEMALE; HIV; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; METHADONE; MIDDLE AGED; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 10744232287     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/379513     Document Type: Article

References (27)

1. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50.
2. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-50.
3. Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992; 268: 504-9.
4. MacGregor RR, Dunbar D, Graziani AL. Tuberculin reactions among attendees at a methadone clinic: relation to infection with the human immunodeficiency virus. Clin Infect Dis 1994; 19:1100-4.
5. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the US among HIV infected persons. Ann Intern Med 1997; 126: 123-32.
6. Centers for Disease Control and Prevention. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic patients at risk of tuberculosis. MMWR 1991; 40:27-33.
7. Centers for Disease Control and Prevention. Case definitions for public health surveillance. MMWR Morb Mortal Wkly Rep 1990; 39:1-43.
8. SAS Institute. SAS/STAT Software: Syntax Version 7. Cary, NC: SAS Institute; 1997.
9. Tuberculosis in New York City, 2000: Information Summary. New York: New York City Department of Health, 2001.
10. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
11. Whalen CC, Johnson, JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-8.
12. Cegielski JP, Chin DP, Espinal MA, et al. The global tuberculosis situation: progress and problems in the 20th century, prospects for the 21st century. Infect Dis Clin North Am 2002; 16:1-58.
13. Frieden TR, Fujiwora PI, Washko RM, Hamburg MA, et al. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 229-33.
14. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4:1026-30.
15. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in patients with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337:315-20.
16. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000; 49:1-54.
17. Centers for Disease Control and Prevention. Severe isoniazid-associated hepatitis - New York, 1991-1993. MMWR Morb Mortal Wkly Rep 1993; 42:545-7.
18. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281:1014-8.
19. Halsey NA, Coberly JS, Desormeaux P, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-1 infected persons: an international randomized trial. Lancet 1998; 351:786-92.
20. Gordin FM, Chaisson RE, Matts JP, et al. An international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283:1445-50.
21. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-5.
22. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47:1-58.
23. Iseman MD. Vaccination to prevent tuberculosis and immuno-dilator therapy for person with active disease. In: Iseman MD, ed. A clinician's guide to tuberculosis. Philadelphia: Lippencott, Williams, and Wilkins, 2000:399-430.
24. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998; 280:72-7.
25. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
26. Santoro-Lopes G, Felix de Pinho AM, Harrison LH, et al. Reduced risk of tuberculosis among Brazilian patients with advanced HIV infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
27. Chaisson RE, Barnes GL, Hackman J, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosiss in injection drug users. Am J Med 2001; 110: 610-5.